Key result
Liraglutide prevents diabetic cardiac dysfunction by activating the PPARα pathway in preclinical models.
Why the study?
Does liraglutide prevent cardiac dysfunction in a rat model of type 2 diabetes?
Does liraglutide prevent cardiac dysfunction in a rat model of type 2 diabetes?
In a diabetic rat model, liraglutide protected against cardiac dysfunction by activating the PPARα pathway, highlighting a potential mechanism for the cardiovascular benefits of GLP-1 receptor agonists.
Answers are grounded in this paper and cite their sources.
Liraglutide may protect cardiac function via PPARα in diabetic rats; extends mechanistic data but leaves open human translation.
Increasing evidence shows that diabetes causes cardiac dysfunction. We hypothesized that a glucagon-like peptide-1 (GLP-1) analog, liraglutide, would attenuate cardiac dysfunction in diabetic rats. A total of 24 Sprague–Dawley (SD) rats were divided into two groups fed either a normal diet (normal, n=6) or a high-fat diet (HFD, n=18) for 4 weeks. Then, the HFD rats were injected with streptozotocin (STZ) to create a diabetic rat model. Diabetic rats were divided into three subgroups receiving vehicle (diabetic, n=6), a low dose of liraglutide (Llirag, 0.2 mg/kg/day, n=6), or a high dose of liraglutide (Hlirag, 0.4 mg/kg/day, n=6). Metabolic parameters, systolic blood pressure (SBP), heart rate (HR), left ventricular (LV) function, and whole genome expression of the heart were determined. Diabetic rats developed insulin resistance, increased blood lipid levels and oxidative stress, and impaired LV function, serum adiponectin, nitric oxide (NO). Liraglutide improved insulin resistance, serum adiponectin, NO, HR, and LV function and reduced blood triglyceride (TG), total cholesterol (TC) levels, and oxidative stress. Moreover, liraglutide increased heart nuclear receptor subfamily 1, group H, member 3 (Nr1h3), peroxisome proliferator activated receptor (Ppar) α (Pparα), and Srebp expression and reduced diacylglycerol O-acyltransferase 1 (Dgat) and angiopoietin-like 3 (Angptl3) expression. Liraglutide prevented cardiac dysfunction by activating the PPARα pathway to inhibit Dgat expression and oxidative stress in diabetic rats.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2018) studied Type 2 diabetes (animal model) (n=24). Liraglutide vs. Vehicle (normal saline) was evaluated on Left ventricular function (LVEDD, LVESD, %FS) and metabolic parameters (p=<0.01). Liraglutide prevented cardiac dysfunction, indicated by decreased LVEDD and LVESD and increased fractional shortening, by activating the PPARα pathway in diabetic rats.
Synapse has enriched 10 related papers. Consider them for comparative context: